Skip to main content
Delfa

← All assets

Rivastigmine

45 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

45

Ongoing

2

Recruiting

1

Completed

38

Sites

841

Countries

38

Endpoints

346

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 346 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
3
Phase 3
14
Phase 4
20
Not applicable
7

Trials by status

Not yet recruiting
1
Recruiting
1
Completed
38
Terminated
3
Unknown
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
70
Safety / tolerability / PK
58
Other (unclassified)
52
Caregiver / quality of life
44
Function / daily living
42
Behavior / neuropsychiatric
34
Other clinical outcomes
20
Executive function / language
15
Neuroimaging
6
Memory
3
Disease progression
1
Amyloid biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 97 of 346 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

36

ADCS-Activities of Daily Living (ADCS-ADL)Function

20

Neuropsychiatric Inventory (NPI)Behavior

20

ADAS-CogCognition

13

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

5

Montreal Cognitive Assessment (MoCA)Cognition

2

Phosphorylated tau 217 (p-tau217)Amyloid

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

45 of 45

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00506415Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Rivastigmine

Alzheimer’s disease

MMSE 10-24Ph 3Completed145May 20112results
MAyflOwer RoADA Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Donepezil, Galantamine, Memantine, Rivastigmine, RO4602522

Alzheimer’s disease

Alzheimer's diseasePh 2Completed142Jun 20151
NCT00623103Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

Rivastigmine

Lewy body dementia

Parkinson's disease dementiaPh 3Completed127Nov 2010-results
ACTIONEffects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed95Jan 20121results
NCT00099242Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed75Jan 20062
NCT00099216Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Rivastigmine

Vascular cognitive impairment / dementia

Study partner/caregiver requiredPh 3Completed63Nov 20051
NCT01614886Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed50May 2014-results
CARECompliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed40Oct 2011-
EXPECTExelon Patch and Combination With Memantine Comparative Trial

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed26Nov 20091
NCT00428389Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed23Feb 20081results
ENA1stepswitchNextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed19May 2018-results
X-MENStudy for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

Rivastigmine

Alzheimer’s disease

Alzheimer's diseaseNot applicableCompleted19Jun 2011-
NCT01399125A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed16May 2013-results
CAREERCognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

Rivastigmine

Alzheimer’s disease

Alzheimer's diseaseNot applicableCompleted16Dec 20161
NCT00000174Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

Rivastigmine

Alzheimer’s disease

CDR global 0.5Ph 3Completed15-1
NCT01529619Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed11Dec 2013-
NCT02989402A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed9Dec 2022-results
BETTERA 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed5Jan 2012-
COMET-ADComparative Research of Alzheimer's Disease Drugs

Donepezil, Galantamine, Rivastigmine

Alzheimer’s disease

Alzheimer's diseaseNot applicableTerminated5Oct 20157results
NCT01585272Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

Rivastigmine

Alzheimer’s disease

mild-to-moderate ADPh 4Completed4Jun 2015-results
NCT00766363Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Donepezil, EVP-6124, Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 1Completed4Mar 2009-results
NCT01183806Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed2Jan 20121
NCT03840837Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Rivastigmine

Lewy body dementia

MoCA 10-25Ph 4Completed1Apr 2020-
EXTRAA 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed1Jan 2009-results
NCT00305903Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease

Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed1Aug 20071

Showing 1-25 of 45 trials